Sinovac (Dalian) Vaccine Technology Co., LTD

Sinovac (Dalian) Vaccine Technology Co., LTD

-- Escort lives and deliver health

Sinovac (Dalian) Vaccine Technology Co., LTD. (hereinafter referred to as "Dalian Sinovac") is a biotechnology high-tech enterprise jointly established by Sinovac Holdings (Hong Kong) Co., LTD and Dalian Kingport Group Co., LTD. Founded in 2010 with registered capital of 348 million YUAN, the company is located in DD Port Industrial Park，Dalian Economic and Technological Development Area. It covers an area of 95,000 square meters, including 52,168 square meters building area. Adhering to the mission of "providing vaccines for the elimination of human diseases", the company is committed to the research, development, production and sales of human vaccines and related products to provide services for the prevention and control of human diseases with the goal of "enabling Chinese children to use world-class vaccines and enabling the world's children to use Vaccines produced in China". Existing staff 531 people, listed products for mumps live attenuated vaccine, live attenuated chicken pox vaccine.

Sinovac's main products are live attenuated mumps vaccine and live attenuated varicella vaccine. Currently, Sinovac has undertaken the production of inactivated COVID-19 vaccine. The company carries the concept that the quality of vaccines comes from the design. The live attenuated mumps vaccines strictly follow the standards of at the beginning of vaccine design, and no antibiotics are added in the whole process of vaccine production. In addition to implementing the 2015 edition of , the quality standards also increase the control requirements of ovalbumin residue, container tightness and vacuum degree, and the safety indicators are stricter than the standards of . The index related to product effectiveness of enterprises (virus titer value) is much higher than enterprise registration standards and national standards. The safety and effectiveness of the product are in the leading level in the industry, and the market share ranks first in domestic product per unit. It is a veritable high-quality vaccine. Since it came into market in 2012, more than 11 million children have been vaccinated against mumps.

After ten years of research and development, Sinovac live attenuated varicella vaccine is cultured with SV-1 cell line with independent intellectual property rights of Sinovac. The first virus harvesting process at home and abroad has broken through the bottleneck of similar products' production capacity and improved product industrialization capacity. At the same time, gelatin-free and blood albumin formulation is adopted to reduce the side reaction rate and the risk of exogenous blood contamination in the inoculation process, which has formed a unique core competitiveness of the industry among similar products. The data from the relevant phase iii clinical study fill in the blank of relevant research data in China and provide scientific data basis for disease prevention. Live attenuated varicella vaccine was registered on 18 December 2019 (Approval Number: S20190044), became the first approved production of vaccine in China since the formal implementation of the Vaccine Management Law of the People's Republic of China, and successfully realized the product on the market in April 2020. Currently, we are promoting the WHO pre-certification, and will further provide safe and high-quality vaccine products for domestic and foreign varicella prevention in the future.

Dalian Sinovac is an independent research and development of biological vaccine production enterprises, taking "drive platform by project construction to platform carry more project industrialization" development strategy, the overall layout, hierarchical propulsion, the key breakthrough, form the enterprise as the research subject, with foreign technical cooperation and combination of research and development mode. Through the joint efforts of multiple platforms, live attenuated mumps and varicella vaccines have been developed and marketed, the pre-clinical study of rubella live attenuated vaccine is completed and has obtained the approval for clinical trial; Oral live rotavirus vaccine, live attenuated herpes zoster vaccine, live attenuated MMR vaccine, MMR varicella quadruple vaccine, etc. are undergoing preclinical studies as planned. Sinovac is the first manufacturer in the world to use the human diploid cell line SV-1, which Sinovac holds its own intellectual property rights, for the development and industrial production of human vaccine system. The core technology of live attenuated varicella vaccine holds many independent intellectual property rights; Relevant research results have been published in internationally renowned journals.

In 2021, according to the global epidemic situation, Sinovac Life Sciences Co., Ltd. entrust Dalian Sinovac set up 4 new production line including 2 assembly line with capacity of 100 million doses and 2 packaging line with capacity of 100 million doses in compliance with relevant national regulations to undertake sub-packaging capacity of 200 million doses of COVID-19 vaccine. With the full coordination and resources of the Liaoning Provincial Medical Products Administration and the project teams of Dalian municipal governments at all levels, Sinovac has reached an annual production capacity of 200 million doses, making its contribution to the fight against COVID-19.

In the future, Dalian Sinovac will remain committed to R&D and production of innovative vaccine for human use, gradually become a leading biological pharmaceutical company in Dalian and northeast regional in the field of vaccine for human use, practice the core concept of the enterprise "escort life, deliver health", to promote science technology innovation of the vaccine industry, bring in and train more innovative talents; build Sinovac Vaccine Industrialization Base into an important human vaccine research and industrialization base for sustainable development in Dalian and establish a century-old enterprise with sustainable development. In addition, the company makes its own contributes to improve the prevention and control level of infectious diseases in the region and even at home and abroad, and bear the responsibility of a vaccine enterprise for the country and society.

Website: http://www.sinovac.com/